On November 14, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security officially issued the 2026 edition of the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List" along with the "Commercial Health Insurance Innovative Drug List," both of which will take effect simultaneously on January 1, 2027.
The most landmark breakthrough in this round is that Relma-cel injection has been transferred from the 2025 commercial insurance innovative drug list into basic medical insurance, becoming the first CAR-T cell therapy product to enter the national basic medical insurance system.
This article uses the industry-standard risk-adjusted net present value (rNPV) model as its foundation, combining the competitive landscape of the sector with post-reimbursement commercialization expectations to estimate the intrinsic value of this pipeline, providing the market with a reference valuation coordinate.
The core logic of rNPV valuation is to discount the future full-lifecycle cash flows of a pipeline to the present point in time after applying multiple risk adjustments. The formula is: peak sales × clinical success probability × discount factor. Peak sales = total target patient population × expected peak penetration rate × market share × annual treatment cost × clinical data quality coefficient × commercialization rights coefficient.
In this assessment, all core indications of the product have already been approved for marketing, so the clinical success probability is taken as 1, and the clinical data quality coefficient is no longer calculated.
Regarding the total patient population, Relma-cel primarily covers three third-line indications for relapsed/refractory B-cell lymphomas, all of which are treatment areas with prominent unmet clinical needs. Among them, R/R LBCL is the most common aggressive B-cell lymphoma subtype, with diffuse large B-cell lymphoma accounting for 35.75% of domestic non-Hodgkin lymphomas, and approximately one-third of patients developing relapsed/refractory disease after first- and second-line standard treatment. According to public data, China has approximately 8,400 new patients annually who fail third-line treatment for R/R LBCL, representing the core eligible population for CAR-T therapy.
R/R FL is the most common indolent B-cell lymphoma in China, accounting for 8.1% to 23.5% of non-Hodgkin lymphomas. Although the disease progresses slowly, it recurs repeatedly, and treatment options are limited for patients with third-line or later relapse. Estimates show that approximately 3,200 R/R FL patients per year meet the criteria for CAR-T treatment. R/R MCL is a highly aggressive lymphoma subtype, with most patients eventually developing treatment resistance and poor prognosis after second-line or later treatment failure. Approximately 3,400 R/R MCL patients per year in China meet the criteria for third-line CAR-T treatment.
After excluding a very small number of overlapping subtype populations across the three major indications, the total annual new target patient population in China meeting CAR-T treatment criteria is approximately 15,000. Combined with the concentrated release of treatment demand from the existing patient pool following medical insurance coverage, the annual addressable target population at peak stage is approximately 15,000.
Penetration rate measures the overall adoption level of the sector, which fundamentally depends on payment accessibility and clinical awareness. Previously constrained by million-yuan-level pricing, the penetration rate of CAR-T therapy among eligible patients in China was less than 2%, far below the level of mature European and American markets. With Relma-cel included in medical insurance, patient out-of-pocket costs have dropped to within 100,000 yuan, significantly lowering the payment threshold. Combined with improved patient disease awareness, accelerated clinical promotion, and expanded treatment center networks, the penetration rate of China's CAR-T sector is expected to continue rising. Taking into account China's medical insurance payment system, patient payment capacity, and clinical practice differences, the overall peak penetration rate of China's CAR-T sector is expected to reach 25% upon entering the mature stage.
From a competitive landscape perspective, China's CD19-targeted B-cell lymphoma CAR-T sector already has four approved products. Relma-cel is currently the only CAR-T product included in national basic medical insurance and exclusively covers both follicular lymphoma and mantle cell lymphoma indications, possessing significant payment-side advantages and indication differentiation advantages. Meanwhile, JW Therapeutics has established a professional commercialization team covering core oncology centers nationwide and possesses mature full-process cell therapy operational capabilities. Considering the competitive landscape and the company's commercialization capabilities, a 50% market share assumption is assigned to Relma-cel.
After the 2026 national medical insurance negotiation, the medical insurance payment standard for Relma-cel injection was set at 288,600 yuan per vial. As an autologous CAR-T cell therapy product, patients need only a single infusion to achieve long-term remission or even clinical cure, without requiring continuous maintenance medication. Therefore, the annual treatment cost is calculated based on a single treatment cost of 288,600 yuan.
Relma-cel was independently developed by JW Therapeutics based on the CAR structure technology platform licensed from Juno. JW Therapeutics holds complete clinical development, manufacturing, and commercialization rights for Greater China and must pay an agreed proportion of sales royalties to the licensor, representing a typical License-in model with localized independent commercialization. According to assessment standards, the commercialization rights coefficient for License-in arrangements requiring medium-level sales royalties ranges from 0.5 to 0.7. Given its independent manufacturing system and self-owned commercialization team operating model, the commercialization rights coefficient is taken as 0.6.
Based on the above parameters, the peak annual sales of Relma-cel in Greater China is approximately 3.247 billion yuan. Regarding the discount factor, JW Therapeutics, as a growth-stage biotech company focused on cellular immunotherapy, has overall pipeline risk higher than mature large pharmaceutical companies, corresponding to a discount rate of 15%, which is within the industry's conventional range. From a time dimension perspective, Relma-cel will officially implement medical insurance pricing in 2027. Cell therapy products typically require a 5-6 year market ramp-up period involving capacity scaling, center expansion, and clinical education to reach peak sales, which is expected around 2032, approximately 6 years from the current point in time. Calculated using the compound discount formula, the discount factor is approximately 0.43.
The final calculation yields a risk-adjusted net present value of approximately 1.396 billion yuan for the Relma-cel Greater China pipeline. It should be noted that this assessment only covers the three approved third-line indications in Greater China and does not include the value of overseas rights or the potential value of subsequent second-line and first-line indication expansions. If future indications successfully move to earlier lines and the patient population expands significantly, there would be substantial upside potential for the pipeline value.
Disclaimer: The peak sales, risk-adjusted net present value, and other data in this article are model estimation results based on public information and a series of subjective assumptions. They are intended solely to demonstrate valuation logic and do not represent official company forecasts, nor do they constitute any investment advice. Key parameters such as penetration rate, market share, and annual treatment cost are subject to significant uncertainty, and actual results may differ materially from the estimated values. Investors should exercise independent judgment and bear investment risks themselves.
Comments